Table 1.
Baseline characteristics of 51 patients receiving raltegravir-based HAART. ANRS CO3 Aquitaine Cohort, 2007–2008.
| Characteristic | Value |
|---|---|
| Sex (M/F), n (%) | 43/8 (84/16) |
| Age, years | 48 (43; 55) |
| Clinical CDC stage (A/B/C), n (%) | 10/24/17 (20/47/33) |
| Follow up time, month | 8(6; 13) |
| Drugs in the OBT | 3 (2; 4) |
| HIV-1 infection duration, years since diagnosis | 17 (14; 20) |
| HIV-1 RNA zenith, log10 copies/mL | 5.4 (4.8; 5.8) |
| CD4+ nadir, cells/mm3 | 90 (33; 175) |
| Baseline HIV-1 RNA level, log10 copies/mL | 4.2 (3.6; 4.7) |
| Baseline CD4+ count, cells/mm3 | 244 (110; 310) |
| Previous antiretroviral therapy | |
| Duration of exposure, years | 10 (6; 12) |
| Previous NRTI, nb | 6 (5; 7) |
| Previous PI, nb | 5 (4; 6) |
| Previous NNRTI, nb | 2(1; 2) |
| Raltegravir co-prescribed antiretrovirals, n (%) | |
| + 2 NRTIs | 18 (35) |
| + 1 PI | 40 (80) |
| + 1 NNRTI | 22 (43) |
| Genotype characteristics at baseline | |
| NRTI resistance-related mutations | 5 (4; 6) |
| PI resistance-related mutations | |
| Minora | 9 (8; 11) |
| Majora | 4 (3; 5) |
| Total (minor + major) | 13 (11; 15) |
| NNRTI resistance-related mutations | 2(1; 3) |
| GSS ANRS (<1/≥1&<2/≥2) | 9/17/25(18/33/49) |
Baseline: Initiation of raltegravir-based HAART. Values are medians (IQR) unless stated otherwise. NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: non-nucleoside reverse-transcriptase inhibitor; PI: protease inhibitor; nb: numbers; OBT: Optimised background therapy;
a
Major and minor protease mutations were defined according to the IAS–USA panel9;
b
GSS: Genotypic sensitivity score of optimized background therapy according to the ANRS algorithms.